The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the industry. A shift away from Schedule I status, often regarded as outdated and hindering https://enrollbookmarks.com/story20685402/pot-rescheduling-a-growth-catalyst